363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result

• Byoung Chul Cho,
• Jin Kyung Lee,
• Jiyeon Ryu,
• Bitna Oh,
• Sunjin Hwang,
• Ki Baik Hahm,
• Seong-Jin Kim,
• Ki Hyeong Lee,
• Ji-Youn Han,
• Byoung Yong Shim,
• Hye Ryun Kim,
• Kyoung-Ho Pyo,
• Jae-Hwan Kim,
• Chung-Feng Xin

Affiliations

Byoung Chul Cho

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, The Republic of Korea

Jin Kyung Lee

4Medpacto, Inc, Seoul, Korea, Republic of

Jiyeon Ryu

5MedPacto,Inc, Seoul, Korea, Republic of

Bitna Oh

5MedPacto,Inc, Seoul, Korea, Republic of

Sunjin Hwang

5MedPacto,Inc, Seoul, Korea, Republic of

Ki Baik Hahm

5MedPacto,Inc, Seoul, Korea, Republic of

Seong-Jin Kim

5MedPacto,Inc, Seoul, Korea, Republic of

Ki Hyeong Lee

2Chungbuk National University Hospital, Cheongju, Korea, Republic of

Ji-Youn Han

3National cancer center, Goyang, Korea, Republic of

Byoung Yong Shim

4ST. Vincent’s Hospital, Suwon, Korea, Republic of

Hye Ryun Kim

1Yonsei Cancer Center, Seoul, Korea, Republic of

Kyoung-Ho Pyo

1Yonsei Cancer Center, Seoul, Korea, Republic of

Jae-Hwan Kim

1Yonsei Cancer Center, Seoul, Korea, Republic of

Chung-Feng Xin

1Yonsei Cancer Center, Seoul, Korea, Republic of